Methylphenidate Hydrochloride Extended Release Capsule

DRUG2 trials

Sponsors

Rhodes Pharmaceuticals, L.P., NYU Langone Health

Conditions

ADHDAttention Deficit Hyperactivity DisorderAttention-deficit/Hyperactivity Disorder

Phase 3

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

CompletedNCT01269463

Rhodes Pharmaceuticals, L.P.ADHD, Attention Deficit Hyperactivity Disorder

Start: 2011-01-19End: 2013-03-13Updated: 2022-12-13

Phase 4

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

RecruitingNCT06577779

NYU Langone HealthAttention-deficit/Hyperactivity Disorder

Start: 2025-01-29End: 2026-10-30Target: 30Updated: 2026-04-29

Related Papers

A Randomized Placebo-Controlled Double-Blind Study Evaluating the Time Course of Response to Methylphenidate Hydrochloride Extended-Release Capsules in Children with Attention-Deficit/Hyperactivity Disorder

Journal of Child and Adolescent Psychopharmacology2014-12-0138 citations